PPARG and neoplasm: A phase-II trial with the sametriple combination in patients with metastatic melanoma or soft-tissue sarcomaevinced disease stabilization [152], indicative of a beneficial effectof COX2 inhibition (whose eicosanoid metabolites activate the ERK cascade) andsimultaneous PPARγ activation in sensitization of tumor cells to differentiation and/orapoptosis.